LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Inicio・Lista de Acciones・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Cerrado

SectorSanidad

3.8 9.51

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.44

Máximo

4.03

Métricas clave
By Trading Economics
Ingresos	-9.4M -118M
Ventas	-29M 6.5M
BPA	-0.22
Margen de beneficios	-1,815.575
Empleados	600
EBITDA	-20M -109M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+104.43% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	93M 2B
Apertura anterior	-5.71
Cierre anterior	3.8

Noticias sobre sentimiento de mercado

By Acuity

50%

155 / 344 Clasificación en Healthcare

Recursion Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

19 feb 2026, 21:28 UTC

Adquisiciones, fusiones, absorciones

Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street. -- Barrons.com

19 feb 2026, 10:27 UTC

Adquisiciones, fusiones, absorciones

Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street. -- Barrons.com

18 feb 2026, 14:52 UTC

Adquisiciones, fusiones, absorciones

Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia. -- Barrons.com

Comparación entre iguales

Cambio de precio

Recursion Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

104.43% repunte

Estimación a 12 Meses

Media 7.38 USD 104.43%

Máximo 10 USD

Mínimo 5.5 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Recursion Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Recursion Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

155 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.